Abstract: Chronic kidney disease (CKD) is widely recognized as one of the leading causes of death worldwide. In order to reduce the incidence of CKD and slow its progression, effective diagnosis, monitoring, treatment, and even preventive measures are urgently needed. In recent years, several large clinical studies have confirmed that sodium glucose transporter 2 inhibitors (SGLT2i) have a renoprotective effect in CKD patients, and can significantly improve the long-term prognosis of CKD patients, but the exact mechanism is still unclear. Exploring the intrinsic mechanism could provide new target strategies for delaying CKD progression. Here, we intend to discuss the mechanism of renal injury in CKD mediated by the Warburg effect related to fructose metabolism and explore the effects of SGLT2i on the Warburg effect.

Key words: Warburg effect, glycolysis, fructose, chronic kidney disease, sodium-glucose cotransporter 2 inhibitors